Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 1,775 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the transaction, the executive vice president owned 23,406 shares in the company, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Monday, March 2nd, Pushkal Garg sold 1,717 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $327.66, for a total value of $562,592.22.
• On Friday, February 13th, Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36.
• On Monday, January 12th, Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Stock Up 2.7%

ALNY stock traded up $8.65 during trading on Wednesday, reaching $327.30. 931,139 shares of the stock were exchanged, compared to its average volume of 1,481,848. The firm’s 50 day moving average is $357.29 and its 200 day moving average is $417.03. The firm has a market cap of $43.41 billion, a P/E ratio of 191.40 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the company posted ($0.65) EPS. The business’s quarterly revenue was up 84.9% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

ALNY has been the subject of several analyst reports. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective for the company. Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 20th. Truist Financial reduced their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Oppenheimer started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $477.96.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Groupama Asset Managment boosted its stake in shares of Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Norges Bank bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $895,816,000. Arrowstreet Capital Limited Partnership boosted its position in Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $369,943,000. Finally, Holocene Advisors LP bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $194,616,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.